ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO962

Neutralising Antibodies Against SARS-CoV-2 and Variants of Concern in In-Centre Haemodialysis Patients in the United Kingdom

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Carr, Edward, The Francis Crick Institute, London, London, United Kingdom
  • Beale, Rupert, The Francis Crick Institute, London, London, United Kingdom

Group or Team Name

  • NAOMI Consortium, Crick COVID Immunity Consortium, Legacy Study Consortium

Haemodialysis patients have significant morbidity and mortality from SARS-CoV-2 infection. In-centre haemodialysis (IC-HD) patients are at particular risk at times of high community transmission as they must attend healthcare settings for life-preserving treatment sessions. In the UK, adenoviral or mRNA vaccines were used for doses 1 and 2 in IC-HD. mRNA vaccines were used for subsequent doses. IC-HD patients are not reported by the phase 3 vaccine trials. Given the coalescence of uraemia, immunosuppressive primary renal diseases and treatments, together with prior experience using other vaccines (for example influenza), we anticipated that IC-HD patients would have an attenuated response to SARS-CoV-2 vaccination.


As a UK-wide consortium, we have used a high-throughput live virus microneutralisation assay to determine the ability of IC-HD patient sera to neutralise ancestral SARS-CoV-2 and variants of concern (VOCs). Ancestral binding Spike antibodies were also assessed by an ancestral S1 ELISA and by a flow cytometry method with full-length trimeric Spike.


We will report IC-HD neutralisation titres after fourth doses and to the newest VOCs, BA.4 and BA.5. Neutralising responses to the first three doses in IC-HD patients are already published by the consortium (Carr et al. The Lancet 2021 and 2022). We will show heterogeneity in the cross-neutralising ability of IC-HD patient sera, and explore how population-level ancestral binding antibody correlations neutralisation titres might not generalise to the individual patient.


Three doses were required for most IC-HD patients to generate neutralising titres against Delta and Omicron BA.1. Further doses are likely required to maintain high serological protection in this vulnerable group of renal patients.


  • Private Foundation Support